225 related articles for article (PubMed ID: 27371967)
1. Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies.
Wright LS; Phipatanakul W
Ann Allergy Asthma Immunol; 2016 Jul; 117(1):17-20. PubMed ID: 27371967
[No Abstract] [Full Text] [Related]
2. Omalizumab: not only for asthma.
Ben-Shoshan M
Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab as add-on therapy to inhaled steroids for asthma.
Hadj Tahar A
Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
[TBL] [Abstract][Full Text] [Related]
4. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
5. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
6. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
8. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
Ohta K; Nagase H; Suzukawa M; Ohta S
Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
[TBL] [Abstract][Full Text] [Related]
9. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with omalizumab in challenge confirmed exercise-induced anaphylaxis.
Christensen MJ; Bindslev-Jensen C
J Allergy Clin Immunol Pract; 2017; 5(1):204-206. PubMed ID: 27839749
[No Abstract] [Full Text] [Related]
11. Roles of omalizumab in various allergic diseases.
Okayama Y; Matsumoto H; Odajima H; Takahagi S; Hide M; Okubo K
Allergol Int; 2020 Apr; 69(2):167-177. PubMed ID: 32067933
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
[TBL] [Abstract][Full Text] [Related]
14. Newer therapies for asthma: a focus on anti-IgE.
Babu KS; Holgate ST
Indian J Chest Dis Allied Sci; 2002; 44(2):107-15. PubMed ID: 12026249
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
16. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
[TBL] [Abstract][Full Text] [Related]
17. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
Heffler E; Fichera S; Nicolosi G; Crimi N
J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855
[No Abstract] [Full Text] [Related]
18. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
[TBL] [Abstract][Full Text] [Related]
19. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
Chang TW; Wu PC; Hsu CL; Hung AF
Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in idiopathic anaphylaxis.
Warrier P; Casale TB
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):257-8. PubMed ID: 19354075
[No Abstract] [Full Text] [Related]
[Next] [New Search]
